Dec 23, 2024 · Hanmi Pharmaceutical is a leading biopharma company in Korea that focuses on providing outstanding medicines developed in-house to medical professionals and patients, as well as concentrating its investments in the R&D of innovative new drugs.

Hanmi Pharmaceutical, boasting the largest pipeline of innovative new drugs in Korea, invites you to explore our overview, vision, values, and corporate identity (CI).

The way to visit Hanmi Pharmaceutical's headquarters and R&D center.

By 2004, Hanmi, outside the top 10 in the industry sales rankings, leaped to become the top-selling company in the Korean pharmaceutical industry. At that time, 'Amodipin', an antihypertensive drug, was Korea's first incrementally modified drug and served as a stepping stone for the explosive growth of Hanmi Pharmaceutical.

Apr 16, 2024 · Hanmi announced that first patient dosing for BH3120 (PD-L1/4-1BB BsAb) commenced on February 13th at a university hospital in South Korea, as part of its global phase 1 trial following registration in January.

Hanmi Pharmaceutical is establishing and executing R&D strategies to create powerful, sustainable, and unprecedented innovations focusing on obesity/metabolism, oncology, and rare diseases with high unmet medical needs.

Hanmi Pharmaceutical provides the best CDMO service to customers worldwide based on its R&D capabilities and state-of-the-art facilities. Hanmi aims to be the best partner in realizing customer-tailored services through skilled professionals and top-notch facilities.

Since its establishment in 1973, Hanmi Pharmaceutical has grown into an R&D-centric company representing Korea. Open Innovation has always been at the center of Hanmi’s “Korean-style R&D,” from first generics to incrementally modified drugs, fixed-dose combinations, and …

Hanmi Pharmaceutical's founder, Lim Sung-ki, pioneered a Korean-style new drug model, initiated the first complex new drug in Korea, and continuously pushed for drug development.

Sep 19, 2024 · The clinical progress for Hanmi's next-generation EZH1/2 dual inhibitor (HM97662), an innovative targeted anticancer agent, has garnered significant attention following presentations at globally renowned oncology conferences.